Skip to content

Author

N. Furubayashi

We have 3 of 78 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Real-World Management and Survival Outcomes in Patients with Primary or Recurrent Retroperitoneal Liposarcoma: A Single-Center Retrospective Cohort Study

Simple Summary Retroperitoneal liposarcoma is a rare cancer whose behavior differs by histological subtype. We reviewed 61 patients with primary or recurrent disease managed at a specialized cancer center, including patients who did not undergo surgery. Among 24 surgically treated patients, macroscopically complete res...

Atsuhiro Kijima, N. Furubayashi, T. Negishi et al. · 0 citations
Review Open access Oct 2026

Prostate-directed Radiotherapy in Selected Patients With Metastatic Castration-sensitive Prostate Cancer: A Real-world Case Series

In this small, highly selected cohort of patients demonstrating favorable initial responses to systemic therapy, prostate-directed RT was feasible and well tolerated, with no grade ≥2 acute RT-related toxicity, no late toxicity among evaluable patients, and no local events.

N. Furubayashi, Takaaki Nakashima, Ryuji Uehara et al. · 0 citations
Review Open access Oct 2026

Clinical Outcomes of Sequential Cabozantinib and Axitinib After First-Line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma: A Single-Center Exploratory Study

Background Evidence regarding sequential vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy after first-line nivolumab plus ipilimumab in advanced renal cell carcinoma (RCC) remains limited. This exploratory study described the clinical outcomes of sequential cabozantinib and axitinib adminis...

N. Furubayashi, Takehito Kojima, Yasuhiro Nakano et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.